0

[Effects of Kavergal on Indices of Lipid Peroxidation and the Condition of the Antioxidant System in Patients With Rheumatic Heart Disease Presenting With Circulatory Insufficiency]

S F Abdullaev, F Kh Inoiatova, F Sh Inoiatov

Lik Sprava. Jul-Sep 2002;(5-6):78-80.

PMID: 12442530

Abstract:

132 patients with rheumatic heart disease presenting with circulatory insufficiency displayed increased LPO both in the blood plasma and red cells, decline in the antioxidant enzymes activity varying with the circulatory insufficiency functional class degree of severity. Basic therapy with making use of antiinflammatory drugs, cardiac glycosides, diuretics together with drugs endowed with an antiarrhythmic activity and nitroglycerin (where indicated) was found to have practically no effect on LPO level or activity of the antioxidant system. The use of the drug kavergal, 1 g three times daily (total daily dosage being 3 g) in the complex therapy, has been shown to significantly decrease hyperlipoperoxidation both in the blood plasma and red cells increasing the activity of enzymes of the antioxidant defence.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
CS37307 Kavergal 1 Kavergal 1 Price
qrcode